23 November 2023 in Clinical and Translational Allergy
Background: Hereditary angioedema (HAE) with C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare disease caused by low level (type I) or dysfunction (type II) of the C1‐inhibitor protein with subsequent reduction of certain complement protein levels.Methods: To develop and test the reliability of a two‐tier method based on C1‐INH and C4 quantitation followed by genetic analysis from dried blood spot (DBS) for establishing the diagnosis of C1‐INH‐HAE. C1‐INH and C4 proteins have been quantified in human plasma using a classical immuno‐assay and in DBS using a newly developed proteolytic liquid chromatography–mass spectrometry method. Genetic analysis was carried out as reported previously (PMID: 35386643) and by a targeted next‐generation sequencing panel, multiplex ligation‐dependent probe amplification and in some cases whole genome sequencing.Results: DBS quantification of C1‐INH and C4 showed the same pattern as plasma, offering the possibility of screening patients with AE symptoms either locally or remotely. Genetic analysis from DBS verified each of the previously identified SERPING1 mutations of the tested C1‐INH‐HAE patients and revealed the presence of other rare variations in genes that may be involved in the pathogenesis of AE episodes.Conclusions: C1‐INH/C4 quantification in DBS can be used for screening of hereditary AE and DNA extracted from dried blood spots is suitable for identifying various types of mutations of the SERPING1 gene.
7 December 2021 in Clinical and Translational Allergy
Background: Angioedemas localized in the upper airway are potentially life threatening, and without proper treatment, they may lead to death by suffocation. Upper airway edemas (UAE) in bradykinin‐mediated angioedemas can even be the first symptoms of the disease.Methods: Our survey was performed with a retrospective long‐term follow‐up method from the medical history of 197 hereditary (C1‐INH‐HAE) and 20 acquired C1‐inhibitor deficiency (C1‐INH‐AAE), 3 factor XII and 3 plasminogen gene mutation (FXII‐HAE, PLG‐HAE) patients treated at our center between 1990 and 2020. The UAE group included edemas localized to the mesopharynx, hypopharynx, and larynx, as narrowing of these anatomical regions can lead to suffocation.Results: 98/197 C1‐INH‐HAE (47 families) and 13/20 C1‐INH‐AAE, 1/3 PLG‐HAE, 1/3 FXII‐HAE patients had experienced UAE at least once according to their medical history. In case of C1‐INH‐HAE patients, in 6/47 families who had undiagnosed ancestors had 13 members who died of suffocation. After the diagnosis, 1‐1 member of two families died of UAE. 44/64 C1‐INH‐HAE patients did not smoke, 20/64 did. The occurrence of UAE was significantly higher in smoker patients. We analyzed 7607 HAE attacks of 56/98 patients. Out of all attacks, the incidence of UAE in the C1‐INH‐HAE group was 4%, and 9.5% in the C1‐INH‐AAE group, respectively.Conclusion: Early diagnosis is key in bradykinin‐mediated angioedemas cases, since the patient must be provided with adequate treatment; and also it is essential to inform patients about the importance of avoiding the trigger factors and the early symptoms of UAE, as these measures could significantly decrease the incidence of lethal UAEs.
14 March 2026 in Orphanet Journal of Rare Diseases
Background: Bradykinin-mediated hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is often hard to differentiate from mast cell (MC) mediated diseases. MCs can be activated by numerous stimuli, leading to the release of various mediators. Recently, crosstalk between MCs and the complement system has been reported. Clinical observations report a higher prevalence of MC-mediated diseases in the HAE-C1INH population than in the general population. Objective: To investigate MC activation in HAE-C1INH. Methods: Serum samples from patients during angioedema attack (HAE-A) and during symptom-free period (HAE-SF), as well as from non-angioedema control subjects were examined. Patients and control subjects had no history of allergic disease and normal levels of both nutritional and inhalant specific IgE. Tryptase, chymase, platelet-activating factor (PAF), leukotriene B4 (LTB4), diamine oxidase (DAO), and eosinophil cationic protein (ECP) were measured. Results: Serum level of chymase was higher in both HAE-C1INH groups than in the control group ( p = 0.020 in both comparisons), while no difference was found between the HAE-A and HAE-SF groups. DAO and ECP did not differ from the control group, but their levels increased during angioedema attack compared to the asymptomatic state ( p = 0.018 and 0.004, respectively). No difference was found in the levels of the other mediators in any comparison. Chymase levels during the symptom-free period were significantly lower in those patients who had more than 3 HAE attack in the three months following sampling than in those who had less than that ( p = 0.012). No other mediators showed a difference between these two groups. Conclusion: Significantly higher chymase levels in HAE-C1INH patients raise the possibility of the activation of a specific subset of MCs in HAE-C1INH patients. Elevation of DAO and ECP levels during HAE attacks indicates the involvement of bradykinin-independent pathways in edema formation during HAE attacks.